Much evidence suggests that targeting the neurotensin (NT) system may provide a novel and promising treatment for schizophrenia. Our recent work shows that: NTS1 knockout (NTS1 
Introduction
The neuropeptide neurotensin (NT) has long been implicated in the pathophysiology of schizophrenia. Antipsychotic drugs increase CSF NT levels in a subset of patients with schizophrenia (Garver et al., 1991; Sherman et al., 1991) and endogenous NT may mediate the effects of antipsychotic drugs through the regulation of dopaminergic, glutamatergic, GABAergic, and 5-HT-mediated circuits in areas associated with the pathophysiology of schizophrenia (Binder et al., 2001) . Therefore, targeting the NT system may provide a novel and promising treatment for schizophrenia (Boules et al., 2003; Breslin et al., 1994; Garver et al., 1991) . NT mediates its effects through its receptors: the high affinity, NT receptor (NTS1), the low affinity NT receptor (NTS2), and NTS3. NTS1 and NTS2 are G-protein coupled, 7-transmembrane spanning proteins, while NTS3 is not so coupled and spans the membrane once. NTS1, the most studied of the NT receptors, modulates dopamine receptors (Fuxe et al., 1992a,b) , mediates several of the central and peripheral effects of NT, and plays a major role in the peptide's modulation of neurotransmitter systems (Antonelli et al., 2007; Leonetti et al., 2004; Pettibone et al., 2002) .
Phencyclidine (PCP), as a non-competitive antagonist of the Nmethyl-D-aspartate (NMDA)/glutamate receptor, induces schizophrenia-like cognitive dysfunction and psychotic behavior in otherwise normal individuals (Javitt and Zukin, 1991; Snyder, 1980) . Thus, PCP administration to rodents has proven to be useful as an animal model for studying schizophrenia (Jentsch and Roth, 1999) . NT69L, an analog of NT (8-13) and an agonist at NTS1 (Tyler-McMahon et al., 2000) and NTS2 (Boules et al., 2010) receptors, blocks behavior and neurochemical changes induced by PCP administration (Li et al., 2010a) . These results suggest that NTS1 is involved in the modulation of PCP-induced schizophrenia-like signs, except that NT69L also affects NTS2. Repeated use of PCP by humans induces more persistent schizophrenic-like signs and symptoms including psychosis, hallucinations, flattened affect, delusions, formal thought disorder, cognitive dysfunction, and social withdrawal (Allen and Young, 1978; Cosgrove and Newell, 1991; Javitt and Zukin, 1991; Rainey and Crowder, 1975) . Therefore, the effects of chronic, rather than acute, exposure to PCP may better represent a model for some facets of schizophrenia.
In recent investigations of NTS1 knockout (NTS1 −/− ) mice from our group (Li et al., 2010b; Liang et al., 2010) , we found that NTS1 −/− mice: 1)
